欢迎来到天天文库
浏览记录
ID:53730117
大小:354.81 KB
页数:4页
时间:2020-04-20
《顺铂同步化疗联合尼妥珠单抗用于局部晚期头颈部鳞癌的近期疗效观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、顺铂同步化疗联合尼妥珠单抗用于局部晚期头颈部鳞癌的近期疗效观察应学明,陈俊,汤声波(南昌大学第一附属医院肿瘤科,南昌330006)中图分类号R730.58文献标志码A文章编号i001.0408(2012)48—4566.04DOI10.6039/j.issn.1001-0408.2012.48.19摘要目的:观察顺铂同步化疗联合尼妥珠单抗治疗局部晚期头颈部鳞癌的近期疗效和不良反应。方法:将58例我院初治局部晚期头颈部鳞癌患者根据入院就诊顺序分A、B组(单号为A组,双号为B组),2组均先行TPF方案(多西紫杉醇75mg·m-,d。+顺铂25m
2、g·m-,d。一氟尿嘧啶600mg·m-,d。_5,每3周重复)诱导化疗2周期,化疗2周期后复查MRJ重新分期评估,除鼻咽癌外能手术者行手术治疗,不能手术者行同步化放疗或联合尼妥珠单抗治疗。A组:行放疗同步每周予顺铂化疗(静脉滴注30mg·m,每周1次,共用6次);B组:在A组的基础上予尼妥珠单抗(放疗前1周静脉滴注200mg,放疗同时静脉滴注100mg,每周1次,共用7次)。治疗结束后评价2组近期疗效和不良反应。结果:中位随访时间为13个月。A、B组的诱导化疗有效率分别为69.0%和79.3%(P=0.368)。A组近期有效率为89.7%
3、,1年生存率为89.7%;B组近期有效率为93.1%,1年生存率为96.6%,B组近期有效率和1年生存率均优于A组,但2组比较差异无统计学意义(P>0.05)。2组主要不良反应为血液学毒性和口腔黏膜炎,发生情况相似,均未观察到超敏反应发生。结论:诱导化疗后同步化放疗联合尼妥珠单抗治疗局部晚期头颈部鳞癌近期疗效确切,患者耐受性较好,不良反应并未因尼妥珠单抗的联合使用而增加,远期疗效尚待观察。关键词局部晚期头颈部鳞癌;同步化疗;顺铂;尼妥珠单抗;近期疗效Short-termEficacyObservationofCisplatinConcurr
4、entChemotherapyCombinedwithNimotuzumabMcAbforLocalAdvancedHeadandNeckSquamousCellCancerYINGXue—ming,CHENJun,TANGSheng—bo(Dept.ofOncology,TheFirstAfiliatedHospitalofNanchangUniversity,Nanchang330006,China)ABSTRACT0BJECTIVE:Tocomp~eshort-termeficacyandadversedrugreactionofci
5、splatinconcurrentchemotherapycorn-binedwithnimotuzumabMcAbforlocaladvancedheadandnecksquamouscellcarcinoma.METHODS:58patientswithlocalad-vancedheadandnecksquamouscellcarcinomawererandomlydividedintogroupAandgroupB(oddnumberincludedingroupA,evennumberincludedingroupB).Bothg
6、roupsreceivedTPFregimen(docetaxel75mg·m~,dl+cisplatin25mg·m~,dt一3+ftuorouracil600mg·m_,d¨,every3weeks),2cyclesofinductionchemotherapy.MRjre—stagingassessmentreviewwascon-ductedafter2cyclesofchemotherapy.Allpatientsunderwentsurgeryexceptnasopharyngealcarcinoma,andinoperable
7、patientsan-derwentchemoradiotherapyorreceivednimotuzumabMcAb.GroupAreceivedchemoradiotherapyandcisplatinchemotherapy(cis-platin:30mg·m',onceaweek,for6weeks).GroupBwasadditionallygivennimotuzumabMcAbonthebasisofgroupA(i.drip200mglweekbeforeradiotherapy,i.drip100mgduringradi
8、otherapy,onceaweek,for7weeks).Short—termeficacyandadversedrugreactionwereevaluatedaftertr
此文档下载收益归作者所有